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Background  and  purpose      Non-steroidal  anti-inflammatory 
drugs (NSAIDs) inhibit cyclooxygenase (COX) activity, which is 
the rate-limiting enzyme in the synthesis of prostaglandins. Previ-
ous studies have indicated that NSAID therapy, and in particular 
NSAIDs that specifically target the inflammatory cyclooxygen-
ase (COX-2), impair bone healing. We compared the effects of 
ibuprofen and rofecoxib on fibula osteotomy healing in rabbits 
to determine whether nominal, continuous inhibition of COX-2 
with rofecoxib would differentially affect fracture healing more 
than cyclical inhibition of COX-2 using ibuprofen, which inhibits 
COX-1 and COX-2 and has a short half-life in vivo. 
Methods   Bilateral fibula osteotomies were done in 67 skeletally 
mature male New Zealand white rabbits. The rabbits were treated 
with placebo, rofecoxib (12.5 mg once a day), or ibuprofen (50 mg 
3 times a day) for 28 days after surgery. Plasma ibuprofen levels 
were measured by HPLC analysis. Bone healing was assessed by 
histomorphometry at 3 and 6 weeks after osteotomy, and at 6 and 
12 weeks by torsional mechanical testing. 
Results   Plasma ibuprofen levels peaked and declined between 
successive doses. Fracture callus morphology was abnormal in the 
rofecoxib-treated rabbits and torsional mechanical testing showed 
that fracture healing was impaired. Ibuprofen treatment caused 
persistence of cartilage within the fracture callus and reduced 
peak torque at 6 weeks after osteotomy as compared to the fibu-
las from the placebo-treated rabbits. In the specimens allowed to 
progress to possible healing, non-union was seen in 5 of the 26 
fibulas from the rofecoxib-treated animals as compared to 1 of 
24 in the placebo group and 1 of 30 in the ibuprofen treatment 
group. 
Interpretation   Continuous COX-2 inhibition as modeled by 
rofecoxib treatment appears to be more deleterious to fracture 
repair than cyclical cyclooxygenase inhibition as modeled by ibu-
profen treatment. Ibuprofen treatment appeared to delay bone 
healing based upon the persistence of cartilage within the frac-
ture callus and diminished shear modulus. Despite the ibupro-
fen-induced delay, rofecoxib treatment produced worse fracture 
(osteotomy) healing than ibuprofen treatment. 

 
There is compelling experimental evidence that non-steroi-
dal anti-inflammatory drug (NSAID) therapy impairs fracture 
healing in various animal models (O’Connor and Lysz 2008). 
Furthermore, NSAID impairment of fracture healing occurs 
by  loss  of  cyclooxygenase-2  (COX-2)  activity  rather  than 
cyclooxygenase-1 (COX-1) activity (Simon et al. 2002). Ret-
rospective studies have also indicated that NSAID therapy can 
increase the incidence of fracture non-unions in humans (Burd 
et al. 2003). Prospective studies have shown that NSAID ther-
apy is clinically useful for reducing the incidence and severity 
of heterotopic ossification (Burd et al. 2001). Thus, NSAID 
treatment has demonstrable effects on bone formation in ani-
mals as well as humans.
Despite the results of these studies, approximately 20% of 
patients treated for long bone fractures in emergency depart-
ments are prescribed NSAIDs to relieve inflammation and pain 
(Petrack et al. 1997). NSAIDs inhibit cyclooxygenase activ-
ity, thus reducing prostaglandin synthesis. In turn, reduced 
prostaglandin synthesis limits inflammation and the develop-
ment of hyperalgesic pain (Steinmeyer 2000). Clearly, many 
of the fractures in patients treated with NSAIDs heal without 
sequelae. Several explanations could be suggested for why 
NSAID therapy is less deleterious for fracture healing in some 
patients than in others. Confounding co-morbidities such as 
age, diabetes, and smoking may have a significant additive 
effect that—when combined with NSAID treatment—severely 
compromises fracture healing.
Another variable that is likely to influence whether NSAID 
therapy impairs fracture healing is the NSAID itself. Duration 
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NSAIDs are used have been shown to substantially affect heal-
ing in an animal model (Simon and O’Connor 2007). In addi-
tion, which NSAID is used is likely to influence healing since 
the pharmacology and specificity of these compounds for the 
2 different cyclooxygenases, COX-1 and COX-2, vary widely 
(Warner et al. 1999). We hypothesized that treatment with a 
traditional NSAID that has a short in vivo half-life (i.e. short-
acting) will lead to daily periods when cyclooxygenase activ-
ity is not inhibited, and thus lead to a better fracture healing 
outcome. To test this hypothesis, we compared fracture heal-
ing using a rabbit fibula osteotomy model in animals treated 
with placebo, a short-acting, traditional NSAID (ibuprofen), 
or a long-acting, COX-2 selective NSAID (rofecoxib). 
Materials and methods
Animal model
All  animal  procedures  were  approved  by  the  New  Jersey 
Medical School Institutional Animal Care and Use Commit-
tee. The study began with 67 skeletally mature, male New 
Zealand White (3.5-kg) rabbits (Table 1). The rabbits were 
acclimated for at least 1 week before surgery and were housed 
individually with a 12-h light-dark cycle and were given water 
and food ad libitum. 3 rabbits died from surgical anesthesia. 
1 rabbit developed ischemia in its right forepaw following 
surgery that necessitated killing. 2 rabbits self-mutilated their 
right forepaw on day 5 post-surgery, which disqualified the 
animals from the study and these rabbits were killed. Ani-
mals were assigned to drug treatment groups based upon day 
of surgery. The surgeons were unaware of the assigned drug 
treatment group until after surgery was completed. Rabbits 
within a treatment group were randomly chosen for killing 
at prescribed time points and for histological or mechanical 
analysis.
Practice  surgeries  were  performed  on  5  separate  rabbits 
that had been used to determine an effective ibuprofen drug 
dose, and they were not included in the total number of ani-
mals in the study (Table 1). All procedures described below 
were applied to the practice surgery rabbits, except that they 
were killed at 2 or 4 weeks after surgery. The practice rab-
bits were not treated with ibuprofen or rofecoxib following 
surgery. Radiographs of the fibula osteotomies demonstrated 
that the fibulas had not bridged with new bone after 4 weeks 
of healing. Mechanical testing of fibula osteotomies would be 
uninformative if the osteotomies in the control rabbits (with 
no drug treatment) had not bridged with bone. Based upon 
these observations, we decided to collect specimens at 6 and 
12 weeks for mechanical testing and 3 and 6 weeks for histo-
logical analysis.
Surgical procedure
Rabbits were fasted overnight before surgery. Each rabbit was 
medicated with glycopyrrolate (0.01 mg/kg) and aceproma-
zine (0.75 mg/kg) as a sedative by intramuscular (IM) injec-
tion. After 15 min, anesthesia was induced with ketamine (55 
mg/kg) and xylazine (5 mg/kg) by IM injection. The rabbit 
was administered morphine (1 mg/kg) for immediate postop-
erative pain relief and enrofloxacin (10 mg/kg) as a prophy-
lactic antibiotic, both by IM injection. The posterior-lateral 
aspect of each hind limb was shaved from below the knee to 
the ankle. The back was shaved above the scapula and one 
half of a 25-μg-per-hour fentanyl patch was applied to this site 
with sutures through the skin, for postoperative pain control. 
The anesthetized rabbit was moved to the surgical table and 
placed supine on a heated pad, and the surgical sites were pre-
pared and draped in a standard fashion. Before surgery, each 
surgical site was injected with 0.5–1 mL of 0.25% bupivacaine 
for pain control.
A 4-cm incision was made on the lateral aspect of each hind 
limb at the mid-diaphyseal level of the fibula. The diaphysis 
of the fibula was exposed by blunt dissection of the overly-
ing muscle and a 1.5-mm-wide osteotomy was created using 
a compressed gas-driven mini-driver with a reciprocating saw 
blade. The wound was irrigated with saline and then closed 
in layers using interrupted, resorbable sutures. It was treated 
with  an  ointment  containing  polymyxin  B,  bacitracin,  and 
neomycin (Triple Antibiotic Ointment; Taro Pharmaceuticals 
USA, Inc., Hawthorne, NY). Postoperative radiographs were 
used to confirm the quality of the osteotomy. For a separate 
experiment, the flexor tendons in the right forepaw of each 
animal were transected and repaired. The skin was closed at 
all incisions with interrupted resorbable sutures and only the 
right forelimb was immobilized with a below-elbow splint. 
Table 1. Disposition of the 67 rabbits used in this study
Treatment  Total   Histology a  Mechanical testing b   Killed before endpoint 
group  no.  3 weeks   6 weeks   6 weeks   12 weeks    Anesthesia  Infection   Ischemia   Self-
            death       mutilation
Placebo   21   3 (6)   3 (5)   6  (11;0;1)    6  (9;1;2)  1   2   –   –
Ibuprofen   25   3 (6)   3 (5)   7  (12;1;1)   8  (12;0;4)   –   1   1   2
Rofecoxib   21   3 (6)   3 (6)   6  (10;2;0)  7  (11;3;0)   2   –   –   – 
a The number of fibulas tested for each group is given in parentheses.
b The disposition of the fibulas for each group is indicated in parentheses (number tested; number of non-unions; number  
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The hind-limbs and left forelimb were not immobilized, and 
were permitted free motion.
Following surgery, the rabbits were allowed to recover in 
heated incubators until the animals were upright, alert, and had 
reached a normal body temperature. They were then returned 
to their cages. Morphine (1 mg/kg IM) was administered 4 and 
8 h post-procedure. An additional dose of enrofloxacin (5 mg/
kg IM) was administered before returning the rabbits to their 
cages after surgery, and then twice a day for the 3 days follow-
ing surgery. The rabbits were permitted free weight bearing 
and unrestricted use of their limbs. The right forepaw splint 
was removed at 14 days. Postoperative, superficial, surgical 
skin wound infections were treated by application of an antibi-
otic ointment, or with intramuscular injections of enrofloxacin 
(10 mg/kg) as directed by the veterinary staff, until the infec-
tion was resolved. The animals were killed by intravenous 
injection of pentobarbital (390 mg) and phenytoin (50 mg).
Drugs and dosing
A pilot study was conducted to identify a suitable ibupro-
fen dose. Rabbits were given an oral dose of ibuprofen and 
peripheral blood was collected from the ear vein for analysis 
of COX-2 activity as an indirect measure of ibuprofen effect. 
COX-2 activity was measured by determining prostaglandin 
E2 levels in blood sera after lipopolysaccharide stimulation, as 
described previously (Brideau et al. 1996). We found that 25-, 
50-, and 100-mg doses of ibuprofen per rabbit (approximately 
7.5, 15, and 30 mg/kg) inhibited COX-2 activity 1 h after oral 
administration. Subsequent experiments using a 50 mg dose 
of ibuprofen per rabbit showed that maximal COX-2 inhibi-
tion occurred between 2 and 4 h after dosing. This was consis-
tent with previous studies showing that peak ibuprofen plasma 
levels occur between 1.5 and 3 h after oral administration, that 
elimination time is dependent upon dose, and that elimination 
half-life is very short: less than 1 h for intravenously admin-
istered ibuprofen (Williams et al. 1991). Thus, we chose to 
use a 50-mg oral dose administered 3 times a day, at least 4 
h apart (150 mg/day). This approximates the recommended 
veterinary dose of 7.5 mg/kg given 4 times a day, which would 
equal approximately 100 mg of ibuprofen per day for a 3.5-kg 
rabbit. The rofecoxib dose of 12.5 mg per rabbit (3.5 mg/kg) 
was based upon a previous study that showed that this dose of 
rofecoxib given orally as a single daily dose impaired bone 
formation in a rabbit model (Goodman et al. 2002). 
Plasma ibuprofen levels were measured using a previously 
described HPLC-based assay to confirm that plasma ibupro-
fen levels varied between doses (Teng et al. 2003). On day 4 
after surgery, blood was collected into heparin from the ear 
vein of 4 ibuprofen-treated rabbits at 1.5, 4, 5.5, 8, and 24 h 
after ibuprofen (50 mg) administration at 0, 4, and 8 h. Plasma 
was separated by centrifugation and stored at –20°C. Aliquots 
of plasma were thawed, spiked with a naproxen internal stan-
dard, and the serum proteins were precipitated as described 
previously (Teng et al. 2003). The resulting supernatant con-
taining the ibuprofen was dried, dissolved in 70% methanol, 
and applied to a C18 reverse-phase column (Zorbax Eclipse 
XDB-C18 5-μm, 4.6 × 150 mm; Aligent, Santa Clara, CA). 
The  column  was  developed  with  40%  water  (the  pH  was 
adjusted to 2.6 with phosphoric acid) and 60% acetonitrile at a 
flow-rate of 2 mL/min and column temperature of 40°C using 
a Dionex GP40 chromatographic HPLC system (Sunnyvale, 
CA). Ibuprofen was detected by absorbance at 220 nm and 
quantified using a standard curve of (±)-ibuprofen (Cayman 
Chemical Co., Ann Arbor, MI). Data from different rabbits 
were normalized as the percentage of the maximum level, 
which occurred at either 1.5 or 5.5 h in all rabbits (Figure 1).
Ibuprofen, rofecoxib, and placebo were given orally to the 
rabbits  via  chewable  tablets.  For  ibuprofen  treatment,  the 
rabbits were given half of a Junior-Strength Advil Chewable 
Tablet (100 mg ibuprofen per tablet; Wyeth Consumer Health-
care, Richmond, VA) 3 times a day. For rofecoxib treatment, 
the rabbits were given one quarter of a custom-made chewable 
tablet (50 mg rofecoxib per tablet) in the morning and then 
one quarter of a chewable placebo tablet (Custom MDs, Bio-
Serv, Frenchtown, NJ) for the remaining doses. The rofecoxib 
chewable  tablets  were  prepared  by  Bio-Serv  from VIOXX 
tablets (Merck, Whitehouse Station, NJ). The placebo-treated 
rabbits were given one quarter of a chewable placebo tablet 3 
times a day. Animals were dosed 3 times a day: in the morning 
(8–9 a.m.), at noon (12–1 p.m.), and in the late afternoon (4–6 
p.m.). The first drug dose was delivered on the morning after 
surgery. Drugs were administered for 28 days after surgery. 
Rabbits were randomized for drug treatment by date of sur-
gery. The surgeons were unaware of the drug treatment regime 
that the rabbits were to undergo following surgery. Rabbits 
within a treatment group were randomly chosen for killing, 
and for histological or mechanical analysis. All histomorpho-
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Figure 1. Variation in plasma ibuprofen levels. Plasma ibuprofen levels 
were statistically elevated 1.5 h after the 8 a.m. and noon doses, but 
had declined by 4 h after dosing. Data were compared to the 24-h 
sample values (16 h after the 4 p.m. dose) and the p-values are indi-
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metric  and  mechanical  testing  procedures  were  performed 
using rabbit identification numbers only, without identifica-
tion as to which drug treatment group or time point the rabbit 
belonged.
Histology
Rabbits were killed at 3 and 6 weeks after surgery for histo-
logical analysis. Fibulas were collected, radiographed, fixed 
in formalin, and embedded in polymethylmethacrylate using 
a previously described technique (Baron et al. 1983). At least 
one longitudinal section through the osteotomy site was cut 
from each fibula and stained with van Gieson’s picrofuchsin 
and Stevenel’s blue to determine the extent of bone healing 
(Maniatopoulos et al. 1986). Digital images of each section 
were captured using a camera and microscope. Histomorpho-
metric measurements of total callus, new bone, and cartilage 
area were made using Image Pro version 5 software (Media 
Cybernetics, Bethesda, MD). The area of each tissue type was 
determined and percentages calculated. Two histological spec-
imens were lost from the study because of preparation errors 
(Table 1). Values for fibulas obtained from the same animal 
were averaged and the mean value was used for subsequent 
calculations and comparisons.
Mechanical testing of fibulas
Fibula samples were collected at 6 and 12 weeks after surgery, 
radiographed, and stored at –20°C before mechanical analysis. 
Osteotomy external callus dimensions were measured with a 
digital caliper prior to testing. The fibulas were potted in one-
inch hex-nuts using Wood’s metal, the gauge length recorded, 
and then each bone was tested to failure in torsion using an 
MTS servo-hydraulic test machine (Eden Prairie, MN) with a 
20-Nm reaction torque cell at a rate of 2 degrees per second. 
Force and angular displacement were recorded every 0.05 sec-
onds. Wall thickness was measured from 6 fibula histological 
specimens described above, and the mean value was used for 
all calculations. Torsional rigidity, polar moment of inertia, 
peak torque, maximum shear stress, and shear modulus were 
calculated as described previously (Simon et al. 2002). Values 
for fibulas obtained from the same animal were averaged and 
the mean value was used for subsequent calculations and com-
parisons.
Of the 80 fibulas that were available for mechanical test-
ing, 15 were lost from the study for different reasons (Table 
1). 2 fibulas were lost during harvest by inadvertent breaking 
before testing, 1 in the 6-week placebo group and 1 in the 6-
week ibuprofen group. One fibula in the 12-week ibuprofen 
group could not be tested because the osteotomy was too distal 
in the bone. Three of the fibulas from the 12-week ibupro-
fen treatment group and 2 fibulas from the 12-week placebo 
group did not fail at or through the fracture site during testing, 
and were disqualified. We suspect that failure at a site other 
than the osteotomy callus indicates that a stress riser may have 
been created during preparation, which led to failure at a non-
osteotomy site. One fibula from the 12-week placebo group, 
1 fibula from the 6-week ibuprofen group, 2 fibulas from the 
6-week rofecoxib group, and 3 fibulas from the 12-week rofe-
coxib group were not tested because of non-unions.
Group sizes and statistics
Differences between treatment groups at each time point were 
assessed by analysis of variance (ANOVA). Since both fibu-
las from the same animal were tested, the outcome parameter 
values for both fibulas were averaged and the average value 
was used for any subsequent analyses. For the 3-week his-
tomorphometry analysis, 3 treatment groups were compared 
using values from 9 rabbits. For the 6-week histomorphom-
etry analysis, 3 treatment groups were compared using values 
from 9 rabbits. For the 6-week mechanical testing analysis, 3 
treatment groups were compared using values from 19 rab-
bits. For the 12-week mechanical analysis, 3 treatment groups 
were compared using values from 19 rabbits. For all ANOVA 
analyses, drug treatment was used as the independent variable 
and the measured outcome parameter was used as the depen-
dent variable. If the overall treatment effect was significant 
(p < 0.05), between-treatment comparisons were performed 
using F-tests. Plasma ibuprofen values were compared to the 
24-h values using ANOVA and post-hoc Holm-Sidak tests. All 
statistical analyses were performed using SigmaStat version 
3 software.
Results
Plasma ibuprofen levels
An HPLC analysis of plasma ibuprofen confirmed preliminary 
experiments and previous reports that ibuprofen is quickly 
eliminated  in  rabbits  (Williams  et  al.  1991).  Rabbits  were 
given 50-mg oral doses of ibuprofen at 8 a.m. (zero time) on 
day 4 after surgery and then at noon (4 h after zero time) and 
at 4 p.m. (8 h after zero time). Blood was collected at 1.5, 4, 
5.5, 8, and 24 h after the initial dose on day 4. Plasma levels 
of ibuprofen were significantly elevated 1.5 h after an oral 
50-mg dose of ibuprofen (1.5- and 5.5-h time points). By 4 h 
after administration (4- and 8-h time points), plasma ibuprofen 
declined to levels that were no different from those in the 24-h 
samples. The mean maximum serum ibuprofen level was 6.7 
μg/mL (SEM 3.3, n = 4).
Histology and radiography
Healing of the rabbit fibula osteotomies was measured after 
3 and 6 weeks by histomorphometry (Figure 2). Longitudinal 
sections parallel to the plane formed by the long axes of the 
tibia and fibula were measured to determine mineralized tissue 
(bone  and  mineralized  cartilage)  and  cartilaginous  tissue 
areas. There were no significant differences in callus area, 
mineralized tissue area, or cartilage area between the placebo, 
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healing. In contrast, at 6 weeks of healing there was 
significantly more cartilage in the osteotomy callus 
of the ibuprofen-treated rabbits than in the placebo- 
or  rofecoxib-treated  rabbits  (Table  2  and  Figure 
3). In addition, there was more overall mineralized 
tissue and callus area in the rabbit fibula osteotomy 
calluses of the rofecoxib treatment group than in the 
ibuprofen or placebo treatment group.
Bone bridging of the osteotomy gap was evident 
in most of the fibulas (Figures 2 and 4). After 12 
weeks of healing, the fibulas from the ibuprofen-
treated  rabbits  appeared  to  be  bridged  with  new 
bone and appeared to have undergone considerable 
remodeling, as callus size appeared smaller (Table 2 
and Figures 2–4). Similar observations were made 
in most of the rofecoxib-treated rabbits except that 
large areas of the callus appeared to be poorly min-
eralized (Figures 2 and 4).
Mechanical testing
7 fibulas were observed to be non-unions and thus 
could  not  undergo  mechanical  testing  (Table  1). 
There  was  1  non-union  in  the  placebo  group,  1 
non-union in the ibuprofen group, and there were 5 
non-unions in the rofecoxib group. Chi-square test 
indicated that the larger proportion of non-unions in 
the rofecoxib group was not significant (p = 0.1). 
The fibulas with a non-union could not be used for 
Figure 2. Representative histological sections through the fibula osteotomy callus. 
Panels A–C show sections from rabbit fibulas after 3 weeks of healing that were 
treated with placebo, ibuprofen, or rofecoxib as indicated. Similarly, panels D–F show 
sections from rabbit fibulas after 6 weeks of healing. Note the shell-like morphology 
of the osteotomy callus in the rofecoxib-treated rabbit after 6 weeks of healing.
Table 2. Summary of fibula histomorphometric analysis
  Group size   Mean (SD)   p-value   Difference in means (95% CI)
  ANOVA  (vs. placebo)  (ibu. vs. rof.)   (vs. placebo)   (ibu. vs. rof.)
 
3 weeks post-fracture
  Callus size (mm2)      0.7
    Placebo   3   27.7 (9.7)    
    Ibuprofen   3  22.6 (2.8)     –      5.1 (-11.2 to 21.3) 
    Rofecoxib   3   27.6 (9.0)     –   –   0.1 (-21.2 to 21.4)   5.0 (-20.2 to 10.2)
  Mineralized tissue (mm2)      0.4
    Placebo   3   11.9 (4.5)    
    Ibuprofen   3     8.3 (1.6)     –      3.6 (-4.1 to 11.3) 
    Rofecoxib   3   13.0 (5.3)     –   –   -1.2 (-12.3 to 10.0)   -4.7 (-13.6 to 4.2)
  Cartilage (mm2)      0.9
    Placebo   3   2.1 (0.8)    
    Ibuprofen   3   2.3 (0.9)     –      -0.3 (-2.2 to 1.6) 
    Rofecoxib   3   1.9 (1.1)     –   –   -0.1 (-2.1 to 2.4)   0.4 (-1.9 to 2.7)
6 weeks post-fracture
  Callus size (mm2)      < 0.05
    Placebo   3   14.7 (3.6)    
    Ibuprofen   3   17.7 (6.1)     0.5      -3.0 (-14.3 to 8.3) 
    Rofecoxib   3   26.8 (4.2)     0.02   0.06   -12.1 (-20.8 to -3.3)   -9.1 (-20.9 to 2.8)
  Mineralized tissue (mm2)      < 0.02
    Placebo   3     7.2 (1.6)    
    Ibuprofen   3     9.2 (3.4)     0.4      -2.0 (-8.1 to 4.1) 
    Rofecoxib   3   15.7 (2.5)     0.007   0.02   -8.5 (-13.210 to -3.781)   -6.5 (-13.3 to 0.3)
  Cartilage (mm2)      0.002
    Placebo   3   0 (0)    
    Ibuprofen   3   0.9 (0.3)     0.001      -0.9 (-1.4 to -0.4) 
    Rofecoxib   3   0.1 (0.2)     0.6   0.002   -0.1 (-0.3 to 0.2)   0.8 (0.3 to 1.4)602  Acta Orthopaedica 2009; 80 (5): 597–605
the  mechanical  testing;  thus,  the  torsional 
mechanical testing data only reflect results 
from  fibulas  in  which  the  osteotomy  was 
bridged with bone. 
The fibular osteotomy sites were measured 
by torsional mechanical testing after 6 and 
12  weeks  of  healing  (Table  3).  Rofecoxib 
treatment  significantly  reduced  the  mate-
rial properties (peak torque and maximum 
rigidity)  and  shear  modulus  of  the  callus 
after 6 weeks of healing as compared to the 
placebo-treated  rabbits. After  12  weeks  of 
healing, no difference was detected between 
the  structural  properties  of  the  rofecoxib-
treated and placebo-treated rabbits, but the 
material properties (maximum shear stress 
and shear modulus) were significantly less. 
Similarly  to  the  placebo  comparison,  the 
material properties of the calluses from the 
rofecoxib-treated rabbits were significantly 
less  than  those  from  the  ibuprofen-treated 
rabbits  after  twelve  weeks  of  healing.  No 
differences in the mechanical properties of 
callus were detected between the ibuprofen-
treated rabbits and the placebo-treated rab-
bits at either time point.
Discussion
As expected from previous studies, rofecoxib 
treatment  impaired  healing  of  the  rabbit 
fibula  osteotomies  (Goodman  et  al.  2002, 
Simon et al. 2002). Rofecoxib treatment ini-
tially led to decreases in the 6-week osteot-
omy callus structural and material properties 
as compared to the placebo-treated rabbits 
(Table 3). 12 weeks after surgery, however, 
rofecoxib  treatment  only  led  to  decreases 
in  callus  material  properties  as  compared 
to the placebo or ibuprofen-treated rabbits. 
The  similarity  in  callus  structural  proper-
ties  between  the  rofecoxib-treated  and  the 
placebo  or  ibuprofen-treated  rabbits  prob-
ably relates to the larger size of the calluses 
in  the  rofecoxib-treated  rabbits  (Table  2), 
which would provide a substantial structural 
advantage despite the apparent poor quality 
of  the  bone—as  reflected  by  its  histologi-
cal  and  radiographic  appearance  (Figures 
2 and 4) and material properties (Table 3). 
While rofecoxib treatment did not ultimately 
prohibit fracture repair in this rabbit study, 
it was clearly detrimental. 5 of the 26 fibu-
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Figure  3.  Histomorphometric  analysis  of  the 
effect of NSAIDs on fracture repair. Shown are 
the mean and standard error after 3 weeks (red 
bars) and 6 weeks (blue bars) of healing for 
callus area (panel A), mineralized tissue area 
(panel  B),  and  cartilage  area  (panel  C).  No 
statistical differences were found after 3 weeks 
of  healing.  Mean  values  that  are  statistically 
significantly  different  from  the  placebo  value 
are indicated with an “a”. Mean values that are 
statistically different between the ibuprofen and 
rofecoxib treatment groups are indicated with 
“b”. 
Figure  4.  Representative  images  of 
the fibula osteotomy calluses: lateral 
radiographs made from the resected 
lower hind limbs of each rabbit at 6 
and  12  weeks  after  osteotomy.  In 
each  radiograph,  the  tibia  cortex 
can be seen on the left margin and 
each  is  oriented  with  the  proximal 
end up. Note the persistence of the 
osteotomy gap after 6 weeks in the 
ibuprofen-treated rabbit, suggesting a 
delay in healing. After 12 weeks, the 
osteotomies in the placebo- and ibu-
profen-treated rabbits appear to have 
healed  well.  In  contrast,  significant 
radiolucent areas are evident in the 
6- and 12-week calluses of the rofe-
coxib-treated rabbits.
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Rofecoxib
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las from the rofecoxib-treated rabbits resulted in non-unions 
as compared to 1 of 24 in the placebo group and 1 of 30 in 
the ibuprofen treatment group. One can assume that the non-
unions would have had very poor mechanical properties; thus, 
our  dataset  positively  skews  the  mechanical  testing  results 
from the rofecoxib treatment group, since non-unions were 
not tested. Consequently, it is likely that we have underesti-
mated the negative mechanical effects of rofecoxib treatment 
on fracture repair in this animal model.
In contrast, ibuprofen treatment delayed healing of the rabbit 
fibula osteotomies—which was evident from the substantial 
amount of cartilage remaining in the osteotomy callus and the 
diminished peak torque after 6 weeks of healing (Tables 2 and 
3). This delay had no apparent lasting effect, however, since 
no differences in the mechanical properties of callus were 
detected between the placebo and ibuprofen treatment groups 
after 12 weeks of healing.
These data support our hypothesis that short-acting NSAID 
therapy is less deleterious to fracture healing than long-acting 
NSAID therapy. A shortcoming of our study is that no experi-
ments were performed to verify plasma levels of rofecoxib in 
the treated rabbits. However, an analysis of plasma ibuprofen 
levels (Figure 1) confirmed our preliminary experiments indi-
cating that a single oral dose of 50 mg ibuprofen provided 
significant COX-2 inhibition for approximately 4 h (between 
1 and 5 h after dosing; data not shown). Thus, we suspect that 
the ibuprofen dosing regimen used allowed consistent inhibi-
tion of COX-2 for no more than 14 h each day. This would 
leave a substantial period of at least 10 h when COX-2 func-
tion was not impaired. 
Unfortunately, the pharmacokinetics of rofecoxib in rab-
bits has not been described in the literature. In male rats, the 
plasma concentration of rofecoxib peaks 0.5 h after adminis-
tration and has a half-life of 4.3 to 6 h, depending upon the 
dose administered (Halpin et al. 2000). Assuming the pharma-
cokinetics of rofecoxib are similar between rats and rabbits, 
then the dose of rofecoxib (approximately 3.5 mg/kg) admin-
istered to the rabbits should have provided substantial COX-2 
inhibition over most of the 24-h dosing cycle. Thus, it would 
appear that during fracture healing, daily periods when COX-
2 activity is not inhibited lead to better healing outcomes than 
when COX-2 activity is continuously inhibited. 
The effects of NSAID treatment on bone healing has been 
extensively  studied  in  animal  models  (O’Connor  and  Lysz 
Table 3. Summary of fibula torsional mechanical testing analysis
  Group    Mean (SD)   p-values   Difference in means (95% CI)
  size  ANOVA  (vs. placebo)  (ibu. vs. rof.)   (vs. placebo)   (ibu. vs. rof.)
6 weeks post-fracture
  Peak torque (Nmm)      0.02
    Placebo   6   227 (38)    
    Ibuprofen   7   181 (43)     0.04      47 (-3 to 96) 
    Rofecoxib   6   165 (26)     0.01   0.5   62 (21 to 104)   16 (-29 to 60)
  Max. rigidity (Nmm2/rad)      0.02
    Placebo   6   7,452 (2,300)    
    Ibuprofen   7   6,175 (1,813)     0.2      1,277 (-1,232 to 3,785) 
    Rofecoxib   6   4,304 (668)     0.006   0.07   3,147 (969 to 5,326)   1,870 (141 to 3,600)
  Max. shear stress (MPa)      0.2
    Placebo   6   36 (8)    
    Ibuprofen   7   33 (15)    –        3.2 (-11.9 to 18.4) 
    Rofecoxib   6   24 (8)     –   –   12.1 (2.1 to 22.1)   8.9 (-6.1 to 23.8)
  Shear modulus (MPa)      < 0.05
    Placebo   6   433 (177)    
    Ibuprofen   7   348 (114)     0.3        86 (-93 to 264) 
    Rofecoxib   6   231 (83)     0.02   0.1   202 (24 to 380)   117 (-7 to 240)
12 weeks post-fracture
  Peak torque (Nmm)       0.3
    Placebo   5   210 (58)    
    Ibuprofen   7   250 (101)     –      -40 (-154 to 73) 
    Rofecoxib   7   185 (47)     –   –     25 (-43 to 92)   65 (-27 to 157)
  Max. rigidity (Nmm2/rad)      0.2
    Placebo   5   8,917 (2,917)    
    Ibuprofen   7   8,690 (4,698)     –         227 (-5,096 to 5,550) 
    Rofecoxib   7   5,766 (1,572)     –   –   3,151 (267 to 6,035)   2,924 (-1,156 to 7,004)
  Max. shear stress (MPa)      0.04
    Placebo   5   51 (17)    
    Ibuprofen   7   53 (22)     0.9       -1.2 (-27.8 to 25.3) 
    Rofecoxib   7   30 (8)     0.04   0.02   21.8 (5.8 to 37.8)   23.0 (3.4 to 42.7)
  Shear modulus (MPa)      < 0.02
    Placebo   5   894 (373)    
    Ibuprofen   7   711 (386)     0.3      184 (-313 to 681) 
    Rofecoxib   7   338 (116)     0.007   0.04   556 (227 to 886)   373 (41 to 705)604  Acta Orthopaedica 2009; 80 (5): 597–605
2008). While most of these studies have concluded that NSAID 
therapy impairs fracture healing, the severity of impairment 
has varied extensively between studies. In our earlier work, 
we found that celecoxib therapy (4 mg/kg per day) appeared 
to impair fracture healing in male rats based upon histological 
and radiographic observations, yet torsional mechanical test-
ing data failed to show any significant difference from control 
specimens after 8 weeks of healing (Simon et al. 2002). In 
a more recent study, we found that celecoxib therapy (4 mg/
kg per day) significantly impaired fracture healing in female 
rats, including torsional mechanical testing data after 8 weeks 
of healing (Simon and O’Connor 2007). A critical difference 
between these studies was the use of male and female rats 
and the dramatic difference in celecoxib elimination times 
between the two sexes. The elimination half-life of celecoxib 
in female rats is 14 h, which is similar to that in humans (Paul-
son et al. 2000). In contrast, the elimination half-life of cele-
coxib in male rats is approximately 4 h. Thus, a single 4 mg/kg 
celecoxib dose can inhibit COX-2 over a 24-h time period in 
female rats but not in male rats.
Based upon the present experimental findings, the differ-
ence in fracture healing outcomes measured between male 
and female rats treated with celecoxib most likely reflects 
the periods each day when COX-2 activity was not inhibited 
in the male rats. Similarly, studies that examined the effects 
of  aspirin,  indomethacin,  ibuprofen,  or  other  short-acting 
NSAIDs on fracture healing have shown a similar pattern of 
impaired healing characterized by a delay rather than com-
plete inhibition of healing (Allen et al. 1980, Altman et al. 
1995).
Together, these animal-based studies suggest that fracture 
patients should avoid using NSAIDs to control fracture pain 
and  inflammation.  However,  if  NSAIDs  are  used,  a  short-
acting NSAID appears to be preferable to using a long-acting 
NSAID. It should be stressed that patients may use large doses 
or more frequent doses of a short-acting NSAID that could 
extend the daily period in which COX-2 is inhibited, and thus 
still potentially delay healing.
The mechanism by which NSAIDs impair fracture healing 
remains unknown. Clearly, NSAIDs inhibit cyclooxygenase 
activity and reduce fracture site prostaglandin levels (Simon 
and O’Connor 2007). However, the question of which pros-
taglandins  are  critical  for  healing,  when  each  is  required, 
from which cells the prostaglandin are made, and which cells 
respond to the prostaglandins is not clear. Infusion of large 
doses of prostaglandin E2 or prostaglandin E2 receptor ago-
nists can promote healing (Keller et al. 1993, Yoshida et al. 
2002, Paralkar et al. 2003). However, it is unclear—given the 
large  doses  of  prostaglandin  E2  or  receptor  agonists—that 
activation of other prostaglandin receptors did not occur or 
that the treatment itself did not induce COX-2 activity, lead-
ing to an indirect activation of other prostaglandin receptors. 
Angiogenesis is necessary for fracture healing, and prosta-
glandins can induce angiogenesis (Hausman et al. 2001, Seno 
et al. 2002). Accordingly, NSAID therapy has been associated 
with  reduced  fracture  callus  blood  flow  (Murnaghan  et  al. 
2006). Whether the NSAID therapy directly impairs angio-
genesis during fracture healing or whether persistence of avas-
cular cartilage in the callus reflects the reduced blood flow still 
remains to be determined.
To  summarize,  we  have  presented  data  supporting  the 
hypothesis that short-acting NSAID therapy (ibuprofen) is less 
deleterious to fracture healing than long-acting NSAIDs (rofe-
coxib). Furthermore, we suggest that this difference may be 
due to daily periods when COX-2 is active in animals treated 
with short-acting NSAIDs. These data may help to resolve 
variations in results found between different animal studies 
that have examined the effects of NSAIDs on fracture healing 
and variations in the clinical experience of many physicians 
and patients who have prescribed or used NSAIDs to control 
pain and inflammation following a fracture.
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